IL22RA2 gene expression in human skin was higher in the epidermal compartment of the skin in comparison with dermis in both healthy skin and psoriasis skin ( Figure 2B ). When comparing expression in samples from healthy controls, psoriasis non-affected skin and psoriasis lesions, a trend towards lower epidermal IL22RA2 expression was noted in lesional psoriasis compared to controls or non-lesional psoriasis in line with the data obtained from imiquimod-treated murine skin.
IL-22 binding protein regulates murine skin inflammation 1 | BACKGROUND
IL-22 is a cytokine expressed by haematopoietic cells of both the innate and adaptive arm of the immune system. [1] Shortly after it was discovered in 2000, the existence of IL-22 binding protein (IL-22BP) was reported, a soluble decoy receptor transcribed from the gene IL22RA2. [2] IL-22BP binds with very high affinity to IL-22 in such a way that it no longer can dock with the IL-22 receptor (IL-22R). [3] It was soon established that IL-22 does not directly influence immune cells but rather the epithelial cells of the skin, lungs, and gut as well as cells of the liver, joints, pancreas, and kidney. [4] These tissues express IL22RA1, one of the two subunits of the IL-22R, whereas the other subunit, IL10RB, is expressed throughout the body. The IL-22 pathway is implicated in several chronic inflammatory diseases, such as psoriasis, inflammatory bowel disease, and multiple sclerosis (MS).
Interestingly, IL-22BP has a protective role in a mouse model of inlammation-induced colon cancer but a disease promoting net effect in a model of MS. [5, 6] Its role in inflammatory skin diseases has so far not been addressed.
| QUESTIONS ADDRESSED
Here, we investigate the role of IL-22BP in murine skin inflammation.
| EXPERIMENTAL DESIGN

Il22ra2
−/− mice were subjected to imiquimod-induced psoriasiform inflammation or oxazolone-induced contact hypersensitivity followed by a comparison of pathological and immunological consequences relative to wild-type mice. For materials and methods, see Appendix S1. Results are reported as group means±SEM, and P-values have been calculated using unpaired Student's t test. Scale bar is 100 μm ear thickness after antigen challenge compared to the wild-type mice;
| RESULTS
Imiquimod-induced inflammation in
however, characterization of the infiltrating immune cells by flow cytometry did not reveal any differences (Fig. S2) .
Next, we sought to elucidate possible mechanisms behind the increased neutrophil infiltration in the imiquimod model, hypothesizing that an increased Th17 response is taking place. Cells from the draining lymph nodes of imiquimod-treated mice were cultured for 3 days with plate bound anti-CD3 followed by analysis by flow We have previously shown that the Il22ra2 −/− mice used in this study have less severe disease in a model of MS. [6] Furthermore, a genetic variant near IL22RA2 has repeatedly been associated with MS susceptibility. [7] Considering the opposite effect observed in the mouse models of MS and psoriasis, we asked whether the G allele of rs17066096, which is positively associated with MS susceptibility, has a protective effect on psoriasis susceptibility or severity. There was, however, no significant difference in the genotype distribution neither when comparing the psoriasis patients with controls nor when comparing psoriasis patients with mild or severe disease, but a trend could be observed that is in line with this hypothesis regarding severity (P=0.29 and OR: 0.9) (Table S1 ).
Another polymorphism in the same locus (rs202573) was included after showing a high odds ratio in a small initial sample comparing mild and severe psoriasis. Incidentally, also this variant has been linked to MS susceptibility in one smaller study. [8] Still, no evidence for association was found after genotyping the whole material.
In wild-type mice, Il22ra2 mRNA levels were markedly decreased by imiquimod treatment (Fig. S4D) . To determine the expression pattern of IL22RA2 in human skin, biopsies were collected from healthy skin and lesional and non-lesional psoriasis skin. Epidermis and dermis were separated using enzymatic digestion prior to RNA preparation.
F I G U R E 2 (A) RT-PCR and Western blot of inflammatory mediators in mouse skin samples collected after imiquimod-induced psoriasiform skin inflammation. RT-PCR data have been pooled from three experiments, n=12. (B) Human skin biopsies were collected from healthy skin, lesional and non-lesional psoriasis (n=8, 8 and 6, respectively). Epidermis and dermis were separated using enzymatic digestion prior to RNA preparation. HPRT was used as reference.
Results are reported as group means±SEM, and P-values have been calculated using unpaired Student's t test
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article. Skin mast cell phenotypes between two highly divergent cohorts -more pronounced variability within than between groups
| BACKGROUND
Mast cells (MCs) are hematopoietic cells that complete their differentiation exclusively in tissues. [1, 2] These unique elements of the human body are the main effector cells of IgE-mediated allergic disorders, but may additionally contribute to various other processes. [1] [2] [3] [4] Our current knowledge of human MCs is limited, partially as a result of the heterogeneous nature of the cells with diversity across types, tissues, subcompartments and differentiation stages ( [5] and references therein). We recently reported that foreskin MCs display interindividual variability but with clear-cut graduation among traits. [5] The skin itself is not a homogeneous organ, but displays diverse features in distinct locations. Thus, the specific requirements of each skin compartment are potential variables to shape its resident MCs.
| QUESTIONS ADDRESSED
We investigated whether MCs from two highly divergent skin subsets (female adult breast skin vs male juvenile foreskin) would display similar
